Bico Group AB. (11/13/23). "Press Release: Maria Forss Assumes Office as BICO’s CEO and President on November 20, 2023".

	Organisation	Bico Group AB (publ)
	Group	Bico (Group)
	Organisation 2	Vitrolife AB
	Group	Vitrolife (Group)
	Product	laboratory equipment and instruments
	Product 2	LIFE SCIENCES
	Person	Forss, Maria (Bico Group 202311– CEO before Vitrolife + AstraZeneca)
	Person 2	Gatenholm, Erik (Cellink 201908 CEO + Co-Founder RESIGNED as CEO of Bico 11/23 LEFT Board 5/24)

Maria Forss assumes office on November 20, 2023, and to ensure a seamless transition, Erik Gatenholm will during a quarter assist with her onboarding process. Thereafter, he will transition into the role as a senior advisor to BICO.

Erik Gatenholm’s remuneration will be less than 50% of his previous compensation. He will not partake in any bonus programs and will decline Board compensation as long as he maintains his operational engagement.

Maria Forss has extensive international experience from leading positions in both medtech and pharma companies, such as Vitrolife and AstraZeneca. The last years within Vitrolife Maria Forss has as the Senior Vice President led the Consumables Business Area and before that she was the Vice President of Business Development and Global Marketing. Maria Forss has successfully developed businesses through the whole value chain and in the whole product life cycle as well as acquisitions and integration of companies.

For more information about the appointment of Maria Forss, please read the press release from August 21, 2023.

For further information, please contact:

Erik Gatenholm, President & CEO, BICO Group AB
Telephone US: +1 (650) 515-5566
Telephone Sweden: +46 73 267 00 00
E-mail: eg@bico.com

Jacob Thordenberg, Chief Financial Officer, BICO Group AB
Phone: +46 73 534 88 84
E-mail: jt@bico.com

The information was submitted for publication, through the agency of the contact persons set out above, on November 13, 2023 at 7.30pm CET.

About BICO

BICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing.

The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.

With 32,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 11,000 publications.

Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction of the world’s organ shortage and speeding up drug development to create the future of life-saving treatments.

BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com

Record changed: 2024-01-20